Homocysteine and Peripheral Arterial Disease: Systematic Review and Meta-analysis

European Journal of Vascular and Endovascular Surgery

Volumn 38, Issue 3, 2009, Pages 316-322

  Khandanpour, N ^a   Loke, Y K ^b   Meyer, F J ^a   Jennings, B ^b   Armon, M P ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Atherosclerosis; Folic acid; Homocysteine; Homocysteine lowering therapy; Intermittent claudication; Peripheral arterial diseases

Indexed keywords

FOLIC ACID; HOMOCYSTEINE;

AMINO ACID BLOOD LEVEL; ARTERY DISEASE; CELL HETEROGENEITY; CLINICAL TRIAL; COCHRANE LIBRARY; DATA BASE; EMBASE; HUMAN; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; TREATMENT OUTCOME; UP-REGULATION;

EID: 68249124870     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2009.05.007     Document Type: Review

References (47)

1. McCully K.S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56 1 (1969 Jul) 111-128
2. Belch J.J., Topol E.J., Agnelli G., Bertrand M., Califf R.M., Clement D.L., et al. Prevention of atherothrombotic disease network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 163 8 (2003 Apr 28) 884-892
3. Boushey C.J., Beresford S.A., Omenn G.S., and Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274 13 (1995 Oct 4) 1049-1057
4. Robinson K., Arheart K., Refsum H., Brattström L., Boers G., Ueland P., et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 97 5 (1998 Feb 10) 437-443
5. Verhoeff B.J., Trip M.D., Prins M.H., Kastelein J.J., and Reitsma P.H. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis 141 1 (1998 Nov) 161-166
6. Wilmink A.B., Welch A.A., Quick C.R., Burns P.J., Hubbard C.S., Bradbury A.W., et al. Dietary folate and vitamin B6 are independent predictors of peripheral arterial occlusive disease. J Vasc Surg 39 3 (2004 Mar) 513-516
7. Ebly E.M., Schaefer J.P., Campbell N.R., and Hogan D.B. Folate status, vascular disease and cognition in elderly Canadians. Age Ageing 27 4 (1998 Jul) 485-491
8. Fowkes F.G., Lee A.J., Hau C.M., Cooke A., Connor J.M., and Lowe G.D. Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risks of peripheral arterial disease and coronary heart disease: Edinburgh Artery Study. Atherosclerosis 150 1 (2000 May) 179-185
9. Daskalopoulou S.S., Pathmarajah M., Kakkos S.K., Daskalopoulos M.E., Holloway P., Mikhailidis D.P., et al. Association between ankle-brachial index and risk factor profile in patients newly diagnosed with intermittent claudication. Circ J 72 3 (2008 Mar) 441-448
10. Jaar B.G., Plantinga L.C., Astor B.C., Fink N.E., Longenecker C., Tracy R.P., et al. Novel and traditional cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients. Adv Chronic Kidney Dis 14 3 (2007 Jul) 304-313
11. Khawaja F.J., Bailey K.R., Turner S.T., Kardia S.L., Mosley Jr. T.H., and Kullo I.J. Association of novel risk factors with the ankle brachial index in African American and non-Hispanic white populations. Mayo Clin Proc 82 6 (2007 Jun) 709-716
12. Goessens B.M., van der Graaf Y., Olijhoek J.K., Visseren F.L., and SMART Study Group. The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg 45 1 (2007 Jan) 47-54
13. van den Berg M., Stehouwer C.D., Bierdrager E., and Rauwerda J.A. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 16 1 (1996 Jan) 165-171
14. Spark J.I., Laws P., and Fitridge R. The incidence of hyperhomocysteinaemia in vascular patients. Eur J Vasc Endovasc Surg 26 5 (2003 Nov) 558-561
15. Sofi F., Lari B., Rogolino A., Marcucci R., Pratesi G., Dorigo W., et al. Thrombophilic risk factors for symptomatic peripheral arterial disease. J Vasc Surg 41 2 (2005 Feb) 255-260
16. Graham I.M. Interactions between homocysteinemia and conventional risk factors in vascular diseases. Eur Heart J 15 Suppl. (1994) 530
17. Ridker P.M., Stampfer M.J., and Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285 19 (2001 May 16) 2481-2485
18. Clarke R., Daley L., Robinson K., Naughten E., Cahalane S., Fowler B., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324 17 (1993) 1149-1155
19. Ciccarone E., Di Castelnuovo A., Assanelli D., Archetti S., Ruggeri G., Salcuni N., et al., GENDIABE Investigators. Homocysteine levels are associated with the severity of peripheral arterial disease in Type 2 diabetic patients. J Thromb Haemost 2 7 (2004 Jul) 1212-1213 author reply 1214
20. van den Bosch M.A., Bloemenkamp D.G., Mali W.P., Kemmeren J.M., Tanis B.C., Algra A., et al. Hyperhomocysteinemia and risk for peripheral arterial occlusive disease in young women. J Vasc Surg 38 4 (2003 Oct) 772-778
21. Taylor Jr. L.M., Moneta G.L., Sexton G.J., Schuff R.A., and Porter J.M. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 29 1 (1999 Jan) 8-19
22. Bloemenkamp D.G., van den Bosch M.A., Mali W.P., Tanis B.C., Rosendaal F.R., Kemmeren J.M., et al. Novel risk factors for peripheral arterial disease in young women. Am J Med 113 6 (2002 Oct 15) 462-467
23. Malinow M.R., Kang S.S., Taylor L.M., Wong P.W., Coull B., Inahara T., et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 79 6 (1989 Jun) 1180-1188
24. Taylor Jr. L.M., DeFrang R.D., Harris Jr. E.J., and Porter J.M. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 13 1 (1991 Jan) 128-136
25. Molgaard J., Malinow M.R., Lassvik C., Holm A.C., Upson B., and Olsson A.G. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Intern Med 231 3 (1992) 273-279
26. Bergmark C., Mansoor M.A., Swedenborg J., de Faire U., Svardal A.M., and Ueland P.M. Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50 - effect of smoking and extent of disease. Eur J Vasc Surg 7 4 (1993Jul) 391-396
27. Mansoor M.A., Bergmark C., Svardal A.M., Lønning P.E., and Ueland P.M. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Arterioscler Thromb Vasc Biol 15 2 (1995 Feb) 232-240
28. Cheng S.W., Ting A.C., and Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg 11 3 (1997 May) 217-223
29. Valentine R.J., Kaplan H.S., Green R., Jacobsen D.W., and Myers S.I. Cl homocysteine, and hypercoagulable states in young men with premature peripheral atherosclerosis. J Vasc Surg 23 1 (1996 Jan) 53-61
30. Erren M., Reinecke H., Junker R., Fobker M., Schulte H., Schurek J.O., et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 19 10 (1999 Oct) 2355-2363
31. Bunout D., Petermann M., Hirsch S., de la Maza P., Suazo M., Barrera G., et al. Low serum folate but normal homocysteine levels in patients with atherosclerotic vascular disease and matched healthy controls. Nutrition 16 6 (2000 Jun) 434-438
32. Rassoul F., Richter V., Janke C., Purschwitz K., Klötzer B., Geisel J., et al. Plasma homocysteine and lipoprotein profile in patients with peripheral arterial occlusive disease. Angiology 51 3 (2000 Mar) 189-196
33. Stricker H., Soldati G., Balmelli T., and Mombelli G. Homocysteine, vitamins and gene mutations in peripheral arterial disease. Blood Coagul Fibrinolysis 12 6 (2001 Sep) 469-475
34. Loncar R., Hrboka V., Tabakovic-Loncar V., Ostojic Z., and Deussen A. Screening of plasma homocysteine in peripheral arterial disease. Ann Med 33 1 (2001 Feb) 48-54
35. Darius H., Pittrow D., Haberl R., Trampisch H.J., Schuster A., Lange S., et al. Are elevated homocysteine plasma levels related to peripheral arterial disease? Results from a cross-sectional study of 6880 primary care patients. Eur J Clin Invest 33 9 (2003 Sep) 751-757
36. Bhargava S., Parakh R., Manocha A., Ali A., and Srivastava L.M. Prevalence of hyperhomocysteinemia in vascular disease: comparative study of thrombotic venous disease vis-à-vis occlusive arterial disease. Vascular 15 3 (2007 May-Jun) 149-153
37. Woo K.S., Chook P., Lolin Y.I., Sanderson J.E., Metreweli C., and Celermajer D.S. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 34 7 (1999 Dec) 2002-2006
38. Mayer O., Filipovský J., Hromádka M., Svobodová V., Racek J., Mayer Jr. O., et al. Treatment of hyperhomocysteinemia with folic acid: effects on homocysteine levels, coagulation status, and oxidative stress markers. J Cardiovasc Pharmacol 39 6 (2002 Jun) 851-857
39. Carrero J.J., López-Huertas E., Salmerón L.M., Baró L., and Ros E. Daily supplementation with (n - 3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. J Nutr 135 6 (2005 Jun) 1393-1399
40. Sydow K., Schwedhelm E., Arakawa N., Bode-Böger S.M., Tsikas D., Hornig B., et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 57 1 (2003 Jan) 244-252
41. Ziegler S., Mittermayer F., Plank C., Minar E., Wolzt M., and Schernthaner G.H. Homocyst(e)ine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease. J Clin Endocrinol Metab 90 4 (2005 Apr) 2175-2178
42. Schernthaner G.H., Plank C., Minar E., Bieglmayer C., Koppensteiner R., and Schernthaner G. No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease. Eur J Clin Invest 36 5 (2006 May) 333-339
43. Brattström L., Israelsson B., Norrving B., Bergqvist D., Thörne J., Hultberg B., et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 81 1 (1990 Feb) 51-60
44. Dudman N.P., Wilcken D.E., Wang J., Lynch J.F., Macey D., and Lundberg P. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler Thromb 13 9 (1993 Sep) 1253-1260
45. Fryer R.H., Wilson B.D., Gubler D.B., Fitzgerald L.A., and Rodgers G.M. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 13 9 (1993 Sep) 1327-1333
46. Wang X., Qin X., Demirtas H., Li J., Mao G., Huo Y., et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369 9576 (2007 Jun 2) 1876-1882
47. Bazzano L.A., Reynolds K., Holder K.N., and He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomised controlled trials. JAMA 296 22 (2006 Dec 13) 2720-2726